McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy

finance.yahoo.com · 2026-09-06

Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]

Read the full story at finance.yahoo.com →